Eli Lilly (NYSE: LLY) has been experiencing fantastic growth due to the success of its GLP-1 drugs, Mounjaro (approved for ...

Amgen may not have an approved GLP-1 treatment just yet, but that could change in the future.

Both companies may succeed in this industry.

Is there another beat-and-raise in the pharmaceutical giant's near future?

Eli Lilly and Company (NYSE:LLY) is among the most profitable healthcare stocks to buy. On January 26, Srikripa Devarakonda, ...

This biotech has candidates in late-stage clinical development.

Eli Lilly and Co (NYSE: LLY) has outperformed the market over the past 5 years by 25.43% on an annualized basis producing an ...

Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...

Eli Lilly signs major deals with Repertoire Immune and Seamless Therapeutics, committing billions to autoimmune disease ...

According to a report by Reuters, Eli Lilly and Company (NYSE:LLY) has signed an agreement worth up to $1.12 billion with ...

There are multiple reasons to hold the stock through the next 20 years. 10 stocks we like better than Eli Lilly › Artificial ...